AbbVie Provides Update on Phase 3 Study of Ibrutinib in Blood Cancer Diffuse Large B-Cell Lymphoma and Ongoing Ibrutinib Clinical Program
AbbVie , a research-based global biopharmaceutical company, announced an update on a Phase 3 study (DBL3001) of ibrutinib (IMBRUVICA®) in untreated diffuse large B-c...





